Highlights of prescribing information these highlights do not include all the information needed to use votrient safely and effectively. If a dose is missed, the patient should not take an additional dose, but should take the next usual. The printed package leaflet of the medicinal product must state the name and. Jakafi ruxolitinib tablets, for oral use initial u. The recommended starting dose of jakafi is based on platelet count table 1. Jakafi is indicated for treatment of patients with polycythemia vera pv who have had an inadequate response to or are intolerant of hydroxyurea.
Anagrelide fda prescribing information, side effects and uses. Jadenu deferasirox tablets, for oral use jadenu sprinkledeferasirox granules, for oral use initial u. Anagrelide is a phosphodiesterase 3 pde3 inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure. The mean baselinecorrected serum calcium for the aredia 60mg and etidronate disodium groups were. Jakafi is indicated for treatment of steroid refractory acute graftversushost disease. Indication for which you are prescribing jakafi ruxolitinib for this patient. It is a cardioprotective agent for use in conjunction with doxorubicin. Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with. Janumetsitagliptinand metformin hydrochloride tablets, for oral use initial u.
Jakafi is approved for use in adults only, and works by blocking the abnormal formation of blood. Fatal andor serious and severe diarrhea or colitis occurred in 14% to 19% of zydeligtreated patients. Official hcp website for zemdri plazomicinan antibiotic indicated for the treatment of complicated urinary tract infections cuti, including pyelonephritis. Carefirst bluecross blueshield is the shared business name of carefirst of maryland, inc. In some cases, health care professionals may use the generic drug name ruxolitinib when referring to the trade name jakafi. This leaflet is part iii of a threepart product monograph. It is an oral receptor tyrosine kinase inhibitor for more detail, see how this drug works, below.
Your healthcare provider may do a pregnancy test before you start treatment with balversa. Twice weekly 2056mgm2 regimen by 30minute infusion kyprolis is administered intravenously as a 30minute infusion on two consecutive days, each week for threeweeks followed by a 12day rest period as shown in table2. Alecensa alectinib capsules, for oral use initial u. Feb 01, 2020 jakafi is indicated for treatment of polycythemia vera pv in adults who have had an inadequate response to or are intolerant of hydroxyurea. Case report aggressive squamous cell carcinoma in a patient on the janus kinase inhibitor ruxolitinib nader aboulfettouh, bs, and rajiv i. Connecticare considers jakafi medically necessary when. Jakafi should be avoided in patients with hepatic impairment with platelet counts less than 100 x 10. Jakafi is the trade for the generic drug ruxolitinib. Aggressive squamous cell carcinoma in a patient on the. The apparent volume of distribution at steady state ranged from 43 to 90 l. Highlights of prescribing information tafinlar with. Combined 2 month dose taper language into a note per prior authorization team request.
Refer to the dexamethasone prescribing information for other information on that product. Jakafi fda prescribing information, side effects and uses. Medscape indication dosing for jakafi ruxolitinib, frequencybased adverse. Votrient pazopanib tablets, for oral use initial u. Inlyta may cause fertility problems in males and females, which may affect your ability to have a child. Highlights of prescribing information patients who have known. Jakafi polycythemia vera, myelofibrosis, acute graft. Libtayo, a programmed death receptor1 pd1 inhibitor, is the first and only fdaapproved therapy indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation 1. Highlights of prescribing information patients with highrisk. Talk to your healthcare provider if this is a concern for you. Zelboraf is not indicated for treatment of patients with wildtype braf melanoma. Highlights of prescribing information these highlights do not include all the information needed to use janumet safely and effectively. Highlights of prescribing information do not coadminister. Monitor for the development of severe diarrhea or colitis.
The nccn drugs and biologics compendium nccn compendium. Highlightsof prescribing information kyprolis safely and. Program prior authorization medication jakafi ruxolitinib issue date 52016 pharmacy and therapeutics approval date 32017 effective date 52017. Hepatotoxicity see full prescribing information for complete boxed warning. Taper jakafi by one dose level approximately every 8 weeks 10 mg twice daily to 5 mg twice daily to 5 mg once daily. Find the patient information for jakafi ruxolitinib, which is indicated for the treatment of adults with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. Zinecard dexrazoxane for injection description zinecard dexrazoxane for injection is a sterile, pyrogenfree lyophilizate intended for intravenous administration.
Equilibrate the refrigerated vial of noxafilposaconazoleinjectionto room temperature. Fda approves incytes jakafitm ruxolitinib for patients with. Inlyta axitinib tablets 2ndline mrcc treatment safety. Highlights of prescribing information these highlights do. Duration oftherapy is based on recovery from neutropenia or immunosuppression. Chemically, dexrazoxane is s4,41methyl1,2ethanediylbis2,6piperazinedione. Jakafi is indicated for treatment of intermediate or highrisk myelofibrosis mf, including primary mf, postpolycythemia vera mf and postessential thrombocythemia mf in adults. Highlights of prescribing information these highlights do not include all the information needed to use jadenu safely and effectively. These highlights do not include all the information needed to use jakafi safely and effectively.
Jakafi ruxolitinib dosing, indications, interactions, adverse effects. You should use effective birth control during treatment and for 1 month after the last dose of balversa. Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis pmf, post polycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Tell your healthcare provider about all the medicines you take, including prescription and overthecounter medicines, vitamins, and herbal supplements. Learn about jakafi ruxolitinib used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, adults with certain types of myelofibrosis, and to treat adults and children 12 years of age and older with acute graftversushost disease who have taken corticosteroids and they did not work well enough. Adverse reactions the most common hematologic adverse. This prescription medicine can help reduce an enlarged spleen and relieve symptoms in people who have this rare disease of the bone marrow. Jakafi is indicated for treatment of steroidrefractory acute graftversushost disease gvhd in adult and pediatric patients 12 years and older. Polycythemia vera o jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response. The starting dose of jakafi is based on patients baseline platelet count. Intravitreal injections, including those with iluvien, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Doses may be titrated based on safety and efficacy. A healthcare provider may recommend jakafi to people who have intermediaterisk or highrisk myelofibrosis. Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate.
Feb 26, 2020 tapering of jakafi may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids. Highlights of prescribing information these highlights do not include all the information needed to use injectafer safely and effectively. Jakafi ruxolitinib is an fdaapproved treatment for adults with intermediate or highrisk myelofibrosis, for adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and for adult and pediatric patients 12 years and older with acute graftversushost disease gvhd who are steroid refractory. First and only fdaapproved treatment for potentially life threatening blood cancer. Zemdri plazomicin injection zemdri official website. Fatal andor serious and severe diarrhea or colitis occurred in 14% to 20% of zydeligtreated patients. Enzalutamides kinetics can be described by a linear 2compartment model with firstorder absorption.
Other drugs that inhibit pde3 have caused decreased survival when compared with placebo in patients with class iiiiv congestive heart failure see drug interactions 7. Jakafi sgm p2016 cvs caremark is an independent company that provides pharmacy benefit management services to carefirst bluecross blueshield and carefirst bluechoice, inc. Jakafi is indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Jakafi ruxolitinib 5mg tablets intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Jakafi ruxolitinib tablets prescribing information.
Thirty patients were randomized to receive aredia and 35 to receive etidronate disodium. Patient information jakafi jakahfye ruxolitinib tablets. Prescribing information, which includes a more complete discussion of the risks associated with jakafi. Accelerated approval was granted for fl and sll based on. Highlights of prescribing information these highlights do not include all the information needed to use alecensa safely and effectively. The recommended starting dose of jakafi is based on platelet count. Jakafi is dosed orally and can be administered with or without food. Following the administration of a single oral dose, the volume of distribution vd is approximately 110 l.
560 633 704 684 1198 975 1280 11 1458 1303 1297 990 847 1149 655 600 1141 1423 1451 536 1232 601 1210 264 348 358 1180 1378 351 600 2 1102 536 412 417 512 201 1194 1315 656 1191 391 339